Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 63% bullish and 36%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $90,860, and 10, calls, for a total amount of $455,657.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $175.0 for AbbVie over the last 3 months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $175.0 in the last 30 days.
AbbVie Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
ABBV | PUT | SWEEP | BEARISH | 11/15/24 | $7.7 | $7.65 | $7.7 | $160.00 | $90.8K | 271 | 0 |
ABBV | CALL | SWEEP | BEARISH | 01/16/26 | $22.95 | $22.2 | $22.2 | $155.00 | $82.1K | 137 | 37 |
ABBV | CALL | TRADE | BULLISH | 08/16/24 | $1.39 | $1.25 | $1.39 | $175.00 | $59.4K | 4.1K | 438 |
ABBV | CALL | TRADE | BULLISH | 07/19/24 | $5.15 | $4.95 | $5.1 | $160.00 | $56.1K | 285 | 135 |
ABBV | CALL | SWEEP | BULLISH | 06/21/24 | $0.63 | $0.58 | $0.63 | $170.00 | $47.2K | 5.2K | 1.0K |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Where Is AbbVie Standing Right Now?
With a trading volume of 2,513,831, the price of ABBV is down by -0.88%, reaching $161.5.
Current RSI values indicate that the stock is may be approaching oversold.
Next earnings report is scheduled for 64 days from now.
What Analysts Are Saying About AbbVie
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $189.0.
Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $200.
Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on AbbVie with a target price of $187.
An analyst from BMO Capital persists with their Outperform rating on AbbVie, maintaining a target price of $180.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.
有大量资金可以花的投资者对艾伯维（纽约证券交易所代码：ABBV）采取了看涨立场。
零售交易者应该知道。
今天，当我们在本辛加追踪的公开期权历史记录中出现头寸时，我们注意到了这一点。
无论这些是机构还是仅仅是富人，我们都不知道。但是，当ABBV发生这么大的事情时，通常意味着有人知道某件事即将发生。
今天，本辛加的期权扫描仪发现了艾伯维的11笔期权交易。
这不正常。
这些大额交易者的整体情绪分为63％看涨和36％（看跌）。
在我们发现的所有期权中，有1个看跌期权，总额为90,860美元，还有10个看涨期权，总额为455,657美元。
预测的价格区间
考虑到这些合约的交易量和未平仓合约，在过去的3个月中，鲸鱼似乎一直将AbbVie的价格定在150.0美元至175.0美元之间。
对交易量和未平仓合约的见解
在交易期权时，查看交易量和未平仓合约是一个强有力的举动。这些数据可以帮助您跟踪给定行使价下艾伯维期权的流动性和利息。下面，我们可以观察过去30天内，艾伯维所有鲸鱼交易的看涨期权和看跌期权交易量和未平仓合约的分别变化，其行使价在150.0美元至175.0美元之间。
过去 30 天的 AbbVie 期权交易量和未平仓合约
检测到的重要期权交易：
符号 | 看跌/看涨 | 交易类型 | 情绪 | Exp。日期 | 问 | 出价 | 价格 | 行使价 | 总交易价格 | 未平仓合约 | 音量 |
|---|
ABBV | PUT | SWEEP | 看跌 | 11/15/24 | 7.7 美元 | 7.65 美元 | 7.7 美元 | 160.00 美元 | 90.8 万美元 | 271 | 0 |
ABBV | CALL | SWEEP | 看跌 | 01/16/26 | 22.95 美元 | 22.2 美元 | 22.2 美元 | 155.00 美元 | 82.1 万美元 | 137 | 37 |
ABBV | CALL | TRADE | 看涨 | 08/16/24 | 1.39 美元 | 1.25 美元 | 1.39 美元 | 175.00 美元 | 59.4 万美元 | 4.1K | 438 |
ABBV | CALL | TRADE | 看涨 | 07/19/24 | 5.15 美元 | 4.95 美元 | 5.1 美元 | 160.00 美元 | 56.1 万美元 | 285 | 135 |
ABBV | CALL | SWEEP | 看涨 | 06/21/24 | 0.63 美元 | 0.58 美元 | 0.63 美元 | 170.00 美元 | 47.2 万美元 | 5.2K | 1.0K |
关于 AbbVie
艾伯维是一家制药公司，在免疫学（与Humira、Skyrizi和Rinvoq合作）和肿瘤学（与Imbruvica和Venclexta合作）方面有着丰富的经验。该公司于2013年初从雅培分拆出来。2020年对Allergan的收购增加了几种美容领域的新产品和药物（包括肉毒杆菌毒素）。
艾伯维现在站在哪里？
分析师对艾伯维的看法
在过去的一个月中，3位行业分析师分享了他们对该股的见解，提出平均目标价为189.0美元。
坎托·菲茨杰拉德的一位分析师将其评级下调至增持，新的目标股价为200美元，这反映了人们的担忧。
巴克莱银行的一位分析师在评估中保持对AbbVie的增持评级，目标价为187美元。
BMO Capital的一位分析师坚持对艾伯维的跑赢大盘评级，维持180美元的目标价。
交易期权涉及更大的风险，但也提供了更高利润的潜力。精明的交易者通过持续的教育、战略贸易调整、利用各种指标以及随时关注市场动态来降低这些风险。使用Benzinga Pro获取实时提醒，随时了解AbbVie的最新期权交易。
